ENHANCING CELL THERAPIES TO IMPROVE RETENTION AND EFFICACY
CL is commercializing an acellular biomaterial developed at the University of Wisconsin-Madison. This biomaterial platform, Tandem™, enables cell therapy delivery, retention, and integration into the damaged tissue, fundamentally enhancing the potential of promising new cell therapies. The company’s initial focus is on the application of its biomaterial to cardiac cell therapies.
Tandem™ HF promises to meaningfully change patient treatment in the aftermath of a heart attack or in the face of other causes of heart failure by delivering the right therapy to the right location in the heart muscle and ensuring that it stays there to promote healing in a minimally invasive procedure.